ATIVAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ativan, and what generic alternatives are available?
Ativan is a drug marketed by Hikma and Bausch and is included in two NDAs.
The generic ingredient in ATIVAN is lorazepam. There are eleven drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the lorazepam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ativan
A generic version of ATIVAN was approved as lorazepam by SANDOZ on April 21st, 1987.
Summary for ATIVAN
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 50 |
| Clinical Trials: | 42 |
| Patent Applications: | 4,490 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ATIVAN |
| What excipients (inactive ingredients) are in ATIVAN? | ATIVAN excipients list |
| DailyMed Link: | ATIVAN at DailyMed |
Recent Clinical Trials for ATIVAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Children's Hospital Los Angeles | Phase 2 |
| University of Colorado, Denver | Phase 2 |
| Jayasree Basivireddy | Phase 3 |
Pharmacology for ATIVAN
| Drug Class | Benzodiazepine |
Anatomical Therapeutic Chemical (ATC) Classes for ATIVAN
US Patents and Regulatory Information for ATIVAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | ATIVAN | lorazepam | INJECTABLE;INJECTION | 018140-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Bausch | ATIVAN | lorazepam | TABLET;ORAL | 017794-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Hikma | ATIVAN | lorazepam | INJECTABLE;INJECTION | 018140-002 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Bausch | ATIVAN | lorazepam | TABLET;ORAL | 017794-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Bausch | ATIVAN | lorazepam | TABLET;ORAL | 017794-003 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ATIVAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hikma | ATIVAN | lorazepam | INJECTABLE;INJECTION | 018140-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Hikma | ATIVAN | lorazepam | INJECTABLE;INJECTION | 018140-002 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ATIVAN
See the table below for patents covering ATIVAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 5024072 | ⤷ Try a Trial | |
| Germany | 2302659 | ⤷ Try a Trial | |
| United Kingdom | 1345510 | ⤷ Try a Trial | |
| Australia | 461715 | ⤷ Try a Trial | |
| Netherlands | 7300694 | ⤷ Try a Trial | |
| South Africa | 7209004 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
